ArticleStem cells translational medicine2014
Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.
Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 70 citations in OpenAlex.
- Mesenchymal Stem Cells in Fungal Infections: Immunomodulation, Direct Antifungal Activity, and the Promise of the Secretome.Biomedicines · 2026Review
- Mesenchymal stem cells for lung diseases: focus on immunomodulatory action.Cell death discovery · 2025Review
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
- Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.Frontiers in microbiology · 2025Review
- Human macrophage migration inhibitory factor potentiates mesenchymal stromal cell efficacy in a clinically relevant model of allergic asthma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.Frontiers in pharmacology · 2023Review
- Dose-dependent effects of human umbilical cord-derived mesenchymal stem cell treatment in hyperoxia-induced lung injury of neonatal rats.Frontiers in pediatrics · 2023Article
- Effects of human adipose tissue- and bone marrow-derived mesenchymal stem cells on airway inflammation and remodeling in a murine model of chronic asthma.Scientific reports · 2022Article
- Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?Frontiers in pharmacology · 2021Review
- Newer Horizon of Mesenchymal Stem Cell-Based Therapy in the Management of SARS-CoV-2-Associated Mucormycosis: A Safe Hope for Future Medicine.Frontiers in microbiology · 2021Review
- Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- A narrative review of research advances in mesenchymal stem cell therapy for asthma.Annals of translational medicine · 2020Review
- Unraveling the therapeutic effects of mesenchymal stem cells in asthma.Stem cell research & therapy · 2020Review
- Evaluation of Human MSCs Treatment Frequency on Airway Inflammation in a Mouse Model of Acute Asthma.Journal of Korean medical science · 2020Article
- Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma.Stem cell research & therapy · 2020Article
- Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma.Stem cells translational medicine · 2020Article
- Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma.Stem cells translational medicine · 2019Article
- hMSCs as an alternative therapeutic option for asthma with neutrophil mediated inflammation.Experimental & molecular medicine · 2018Article
- Human iPSC-MSCs prevent steroid-resistant neutrophilic airway inflammation via modulating Th17 phenotypes.Stem cell research & therapy · 2018Article
- Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Systemic administration of mesenchymal stromal cells (MSCs) suppresses airway inflammation and methacholine-induced airway hyper-responsiveness (AHR) in mouse models of T helper cell (Th) type 2-mediated eosinophilic allergic airway inflammation (AAI); however, the efficacy of MSCs in mouse models of severe Th17-mediated neutrophilic AAI has not yet been demonstrated. We assessed MSC effects in a mouse model of mixed Th2/Th17 AAI produced by mucosal exposure to Aspergillus fumigatus hyphal extract (AHE). Following sensitization produced by oropharyngeal AHE administration, systemic (tail vein) administration of syngeneic MSCs on the first day of challenge significantly reduced acute AHR predominantly through reduction of Th17-mediated airway inflammation. In parallel experiments, MSCs also mitigated AHR when administered during recurrent challenge 10 weeks after initial sensitization and challenge through reduction in systemic Th17-mediated inflammation. Investigation into potential mechanistic actions of MSCs in this model demonstrated that although T regulatory cells were increased in all AHE-treated mice, MSC administration did not alter T regulatory cell numbers in either the acute or recurrent model. Differential induction of interleukin-17a secretion was observed in ex vivo restimulation of mediastinal lymph node mixed-cell cytokine analyses. Although the mechanisms by which MSCs act to decrease inflammation and AHR in this model are not yet fully elucidated, decrease in Th17-mediated airway inflammation appears to play a significant role. These results provide a basis for further investigations of MSC administration as a potential therapeutic approach for severe refractory neutrophilic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.